2. Search Result
Search Result
Results for "

Fucose deficiency

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

12

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99113A
    Inebilizumab (FUT8-KO)

    		CD19 Inflammation/Immunology
    Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
    Inebilizumab (FUT8-KO)
  • HY-P99010A
    Bemarituzumab (FUT8-KO)

    		Interleukin Related FGFR Cancer
    Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
    Bemarituzumab (FUT8-KO)
  • HY-P9977A
    Amivantamab (FUT8-KO)

    		EGFR Cancer
    Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
    Amivantamab (FUT8-KO)
  • HY-P9980A
    Belantamab (FUT8-KO)

    		ADC Antibody TNF Receptor Cancer
    Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
    Belantamab (FUT8-KO)
  • HY-P9991A
    Osemitamab (FUT8-KO)

    		Gap Junction Protein Cancer
    Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
    Osemitamab (FUT8-KO)
  • HY-P990755A
    Pamvatamig (FUT8-KO)

    		EGFR Cancer
    Pamvatamig (FUT8-KO) is an anti-EGFR/MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody.
    Pamvatamig (FUT8-KO)
  • HY-P99226A
    Daxdilimab (FUT8-KO)

    		Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Inflammation/Immunology
    Daxdilimab (FUT8-KO) is an anti-ILT7 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
    Daxdilimab (FUT8-KO)
  • HY-P991944A
    ZL-1218 (FUT8-KO)

    		CCR Cancer
    ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .
    ZL-1218 (FUT8-KO)
  • HY-P991481A
    S-531011 (FUT8-KO)

    		CCR Inflammation/Immunology Cancer
    S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity .
    S-531011 (FUT8-KO)
  • HY-P991135A
    Enzelkitug (FUT8-KO)

    RO-7502175 (FUT8-KO); RG-6411 (FUT8-KO)

    		 CCR Cancer
    Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies .
    Enzelkitug (FUT8-KO)
  • HY-P991942A
    Lanerkitug (FUT8-KO)

    BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)

    		 CCR Cancer
    Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
    Lanerkitug (FUT8-KO)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: